Skip to main content

Table 4 Guidance statement for elosulfase alfa

From: Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance

Statement Percentage consensus
Initiation of long-term ERT with elosulfase alfa at a dose of 2.0 mg/kg/week through intravenous infusion is recommended in all patients with MPS IVA as soon as possible after a confirmed diagnosis
Evidence Grade: B (level 2 or 3 studies)
79%